Poiată Antonia, Tuchiluş Cristina, Bădicuţ Ioana, Grigore Lucia, Buiuc D
Gr. T. Popa University of Medicine and Pharmacy, Faculty of Pharmacy, Microbiology Department, Iaşi, Romania.
Roum Arch Microbiol Immunol. 2002 Oct-Dec;61(4):293-9.
Linezolid is a member of the new class of antibacterial agents called oxazolidinones that are active against Gram positive organisms and exert their action by protein synthesis inhibition. In this study we investigated the in vitro activity of linezolid versus the other agent against clinical strains of staphylococci: Staphylococcus aureus (n = 82) and S. epidermidis (n = 32) collected in 2002 from hospitalized patients and healthy individuals, isolated from different biological samples. Agar dilution minimum inhibitory concentrations (MICs) were determined by using Mueller-Hinton agar according to the guidelines established by the National Committee for Clinical Laboratory Standards. Linezolid demonstrated excellent in vitro activity against all isolates tested, with MICs values in the range of susceptibility (< or = 8 microg/ml). No associated resistance between linezolid and other agents tested was observed. The resistance among Gram positive bacteria continues to spread and for many patients infected with these resistant organisms antimicrobial therapy is ineffective and linezolid may be a new alternative treatment.
利奈唑胺是一类名为恶唑烷酮类的新型抗菌药物中的一员,这类药物对革兰氏阳性菌有活性,并通过抑制蛋白质合成发挥作用。在本研究中,我们调查了利奈唑胺与其他药物对葡萄球菌临床菌株的体外活性:2002年从住院患者和健康个体中收集的金黄色葡萄球菌(n = 82)和表皮葡萄球菌(n = 32),这些菌株从不同生物样本中分离得到。根据美国国家临床实验室标准委员会制定的指南,使用穆勒-欣顿琼脂测定琼脂稀释最低抑菌浓度(MICs)。利奈唑胺对所有测试分离株均表现出优异的体外活性,MIC值处于敏感范围(≤8微克/毫升)。未观察到利奈唑胺与其他测试药物之间存在相关耐药性。革兰氏阳性菌中的耐药性持续蔓延,对于许多感染这些耐药菌的患者,抗菌治疗无效,而利奈唑胺可能是一种新的替代治疗方法。